There's one drawback to having the stock market indexes hit record highs yet again: It makes finding truly horrendous health-care stocks for our weekly series much more challenging. But the Fool is always...... (read more)

Biotech investors rejoice. The ASCO abstracts are here. The annual meeting of the American Society of Clinical Oncology starts on May 31, but the organization releases most of the 4,700 abstracts -- available...... (read more)

Gilead Sciences, Inc. (NASDAQ:GILD) reported a relatively rare earnings miss in the first quarter on May 2. The biotech announced earnings of $0.48 per share while analysts were expecting $0.50 per share...... (read more)

The Centers for Disease Control and Prevention would put heart disease at the top of the list, since it's the leading cause of death in the nation. If we looked to Google for an answer, Americans searched...... (read more)

What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest. Some take what we at the Fool call a "motley approach" and try a little bit...... (read more)

Gilead Sciences, Inc. (NASDAQ:GILD) has exploded over the last few years as a powerhouse of anti-viral medications.  Its myriad treatments for HIV have brought in $2 billion in Q1 alone, and its hepatitis...... (read more)

Investing in biotech companies can be intimidating, especially for investors without a science background. But there's hope. Understanding the naming system can make things easier to piece together, giving...... (read more)

Proponents of income investing may not like it, but there is nothing like a growth portfolio, portions of which can be sold at higher prices to rival the benefits of a dividend portfolio. Buying at lower...... (read more)

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year. Vertex is a biotech company...... (read more)